Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Holtzman

Showing results (241-250 of 293) with videos related to

Pageof 30
Sort By:
Acta Haematologica|May 8, 2018
Sickle Cell Disease Complicated by Iron Overload: An Under-Recognized Risk Factor for Vibrio vulnificus InfectionFiras El Chaer, Noa G Holtzman, Maria R Baer, et al.
Psychopharmacology|March 21, 2001
Agonist efficacy, drug dependence, and medications development: preclinical evaluation of opioid, dopaminergic, and GABAA-ergic ligandsJ Bergman, C P France, S G Holtzman, et al.
Clinical Case Reports|November 21, 2017
Promyelocytic sarcoma of the right humerus: an unusual clinical presentation with unique diagnostic and treatment considerationsSameer Sawhney, Noa G Holtzman, Derik L Davis, et al.
Psychopharmacology|October 1, 1994
Individual differences in behavior following amphetamine, GBR-12909, or apomorphine but not SKF-38393 or quinpiroleM S Hooks, D N Jones, S G Holtzman, et al.
NIDA Research Monograph|January 1, 1996
Caffeine: a model drug of abuseR R Griffiths, S G Holtzman, J W Daly, et al.
European Journal of Pharmacology|July 6, 2007
The CRF1 receptor antagonist, R121919, attenuates the severity of precipitated morphine withdrawalKelly H Skelton, Dana Oren, David A Gutman, et al.
Cancers|June 19, 2024
A Clinical Perspective on Plasma Cell Leukemia: A Single-Center ExperienceAndrew Y Li, Farin Kamangar, Noa G Holtzman, et al.
Journal of Medicinal Chemistry|March 12, 1999
Synthesis and pharmacology of site-specific cocaine abuse treatment agents: 2-(aminomethyl)-3-phenylbicyclo[2.2.2]- and -[2.2.1]alkane dopamine uptake inhibitorsH M Deutsch, D M Collard, L Zhang, et al.
Blood Advances|December 7, 2020
Safety and efficacy of CAR T cells in a patient with lymphoma and a coexisting autoimmune neuropathyKhushali S Jhaveri, Ilana Schlam, Noa G Holtzman, et al.
Haematologica|August 16, 2023
Red cell distribution width as a new prognostic biomarker in refractory chronic graft-<i>versus</i>-host diseaseEduard Schulz, Filip Pirsl, Noa G Holtzman, et al.
Pageof 30

Showing results (241-250 of 293) with videos related to

Sort By:
Pageof 30
Acta Haematologica|May 8, 2018
Sickle Cell Disease Complicated by Iron Overload: An Under-Recognized Risk Factor for Vibrio vulnificus InfectionFiras El Chaer, Noa G Holtzman, Maria R Baer, et al.
Psychopharmacology|March 21, 2001
Agonist efficacy, drug dependence, and medications development: preclinical evaluation of opioid, dopaminergic, and GABAA-ergic ligandsJ Bergman, C P France, S G Holtzman, et al.
Clinical Case Reports|November 21, 2017
Promyelocytic sarcoma of the right humerus: an unusual clinical presentation with unique diagnostic and treatment considerationsSameer Sawhney, Noa G Holtzman, Derik L Davis, et al.
Psychopharmacology|October 1, 1994
Individual differences in behavior following amphetamine, GBR-12909, or apomorphine but not SKF-38393 or quinpiroleM S Hooks, D N Jones, S G Holtzman, et al.
NIDA Research Monograph|January 1, 1996
Caffeine: a model drug of abuseR R Griffiths, S G Holtzman, J W Daly, et al.
European Journal of Pharmacology|July 6, 2007
The CRF1 receptor antagonist, R121919, attenuates the severity of precipitated morphine withdrawalKelly H Skelton, Dana Oren, David A Gutman, et al.
Cancers|June 19, 2024
A Clinical Perspective on Plasma Cell Leukemia: A Single-Center ExperienceAndrew Y Li, Farin Kamangar, Noa G Holtzman, et al.
Journal of Medicinal Chemistry|March 12, 1999
Synthesis and pharmacology of site-specific cocaine abuse treatment agents: 2-(aminomethyl)-3-phenylbicyclo[2.2.2]- and -[2.2.1]alkane dopamine uptake inhibitorsH M Deutsch, D M Collard, L Zhang, et al.
Blood Advances|December 7, 2020
Safety and efficacy of CAR T cells in a patient with lymphoma and a coexisting autoimmune neuropathyKhushali S Jhaveri, Ilana Schlam, Noa G Holtzman, et al.
Haematologica|August 16, 2023
Red cell distribution width as a new prognostic biomarker in refractory chronic graft-<i>versus</i>-host diseaseEduard Schulz, Filip Pirsl, Noa G Holtzman, et al.
Pageof 30